MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$31,454K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Stock-based compensation expense
Accrued expenses
Others
Negative Cash Flow Breakdown
Purchases of investments
Net loss
Accretion of investment discount...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-43,423
-41,284
-32,999
-34,386
Stock-based compensation expense
8,318
6,120
6,386
7,076
Depreciation expense
43
98
108
120
Accretion of investment discounts, net
1,217
609
1,057
1,243
Charge for in-process research and development ('ipr&d') milestones
0
4,000
-
-
Other non-cash items
-31
-53
433
0
Accounts receivable, net
-
-
-44
30
Interest receivable
-
-
-6
55
Prepaid expenses and other current assets
325
-1,433
-2,658
3,221
Operating lease right-of-use assets
340
300
295
336
Other assets
-
26
-
0
Deposits and other assets
2
-
1,976
-
Accounts payable
2,004
10
275
-33
Accrued expenses
3,180
-6,674
-1,209
1,095
Operating lease liabilities
-375
-327
23
-27
Net cash used in operating activities
-31,424
-36,882
-27,903
-30,368
Purchases of property and equipment
30
-
86
24
Milestone payments related to ipr&d
0
4,000
-
-
Purchases of investments
180,767
19,738
30,446
58,740
Proceeds from maturities of marketable securities
31,000
60,000
60,000
64,000
Net cash used in investing activities
-149,797
36,262
29,468
5,236
Proceeds from financings, net of issuance costs
-
-
-375
191,111
Proceeds from exercise of stock options and rsus vesting
1,973
7,159
376
2,659
Withholding taxes paid on stock-based awards
494
3,942
209
2,164
Net cash provided by financing activities
1,479
3,217
-208
191,606
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents
-68
-111
118
151
Net decrease in cash, cash equivalents and restricted cash equivalents
-179,810
2,486
1,475
166,625
Cash, cash equivalents and restricted cash equivalents, beginning of period
230,122
227,636
226,161
78,837
Cash, cash equivalents and restricted cash equivalents, end of period
50,312
230,122
227,636
226,161
Cash and cash equivalents
49,326
-
-
-
Restricted cash equivalents
986
-
-
-
Total cash, cash equivalents and restricted cash equivalents
50,312
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
stock options and rsus...
$1,973K
(89.35%↑ Y/Y)
Net cash provided by
financing activities
$1,479K
(-97.75%↓ Y/Y)
Canceled cashflow
$494K
Net decrease in
cash, cash...
-$179,810K
(-831.61%↓ Y/Y)
Canceled cashflow
$1,479K
Proceeds from maturities
of marketable...
$31,000K
(-74.59%↓ Y/Y)
Stock-based compensation
expense
$8,318K
(-41.35%↓ Y/Y)
Accrued expenses
$3,180K
(149.04%↑ Y/Y)
Accounts payable
$2,004K
(492.90%↑ Y/Y)
Operating lease
right-of-use assets
$340K
(-69.06%↓ Y/Y)
Depreciation expense
$43K
(-85.52%↓ Y/Y)
Other non-cash items
-$31K
(88.26%↑ Y/Y)
Withholding taxes paid on
stock-based awards
$494K
(-50.00%↓ Y/Y)
Net cash used in
investing activities
-$149,797K
(-624.88%↓ Y/Y)
Net cash used in
operating activities
-$31,424K
(51.71%↑ Y/Y)
Canceled cashflow
$31,000K
Canceled cashflow
$13,916K
Effect of exchange rate
changes on cash, cash...
-$68K
(-108.45%↓ Y/Y)
Purchases of investments
$180,767K
(26.73%↑ Y/Y)
Net loss
-$43,423K
(43.86%↑ Y/Y)
Purchases of property and
equipment
$30K
(7.14%↑ Y/Y)
Accretion of investment
discounts, net
$1,217K
(-62.28%↓ Y/Y)
Operating lease
liabilities
-$375K
(67.62%↑ Y/Y)
Prepaid expenses and
other current assets
$325K
(104.98%↑ Y/Y)
Buy us a coffee
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)